This FAQ from Springs Clinic, authored by Dr. Charles Pereyra, provides a comprehensive overview of the clinic’s mesenchymal stem cell (MSC) and exosome-based therapies for hair restoration and joint/cartilage repair. It explains that these biologics are not FDA‑approved for most indications, though they may be used under the 361 cosmetic pathway and emerging state laws. The document defines MSCs versus pluripotent stem cells, describes exosomes (non‑living vesicles containing microRNA, proteins, and growth factors), and outlines their cellular uptake via endocytosis. Clinical protocols are detailed, notably the three‑step STEM3 regimen that combines MSC‑derived exosomes, specific peptides (e.g., GHK‑CU), and micro‑FUE for hair, as well as a hyper‑PRP‑enhanced exosome solution for joints. Reported outcomes include treatment of ~7,000 patients with a 98% hair‑regrowth success rate when the full protocol is followed, and performance guarantees (free repeat injections, 10‑year pain‑management support). Safety is emphasized through CGMP‑compliant manufacturing, third‑party testing (particle counts, CD markers, sterility), and a claim of zero major adverse events across clinics in California, Florida, Texas, New York, and Georgia. The FAQ also addresses cost justification, side‑effect profile (minimal redness, no cancer or anaphylaxis observed), and criteria for using live MSCs in refractory cases. Overall, the document serves as a persuasive, informational guide to the clinic’s regenerative medicine offerings, highlighting mechanisms, regulatory context, clinical results, and patient guarantees.
Topics
Regulatory Landscape: 361 Pathway and State Laws vs FDA Approval
Explanation that MSC and exosome therapies are not FDA‑approved for most conditions, but may be used cosmetically under the 361 pathway and recent state legislation (e.g., Florida 2025).
Mesenchymal Stem Cells: Definition, Function, and Differentiation
Distinguishes MSCs from pluripotent stem cells, outlines their adult lineage, anti‑inflammatory signaling, tissue rejuvenation, and ability to attach to damaged tissue and differentiate (e.g., into chondrocytes).
Exosomes: Composition, Cellular Uptake, and Safety Profile
Describes exosomes as non‑living vesicles (~100 nm) containing microRNA, proteins, and growth factors; explains endocytosis mechanism; highlights ability to cross blood‑brain barrier and lack of major adverse events in 7,000 patients.
Clinical Protocols and Success Guarantees (STEM3 and Joint Regeneration)
Details the three‑step STEM3 protocol for hair (exosomes + peptides + micro‑FUE) with 98% success when fully applied; outlines joint protocol using exosome‑hyperPRP blend; describes performance guarantees (free repeat, 10‑year pain support).
Safety Measures, Testing, and CGMP Compliance
Outlines third‑party testing (particle counters, CD markers, sterility), certificates of analysis, CGMP‑grade labs, and board‑certified clinicians; reports zero major adverse reactions, only minor transient redness/swelling.
Cost Justification and Value Proposition
Explains high cost due to umbilical‑cord harvesting, rigorous sterility, extensive testing, and clinician oversight; contrasts with cheaper alternatives and includes free‑repeat and transplant credit guarantees.
Indications and Mechanistic Rationale: Hair Regrowth
Shows how exosomes activate LEF1, reduce inflammation, and deliver VEGF to promote follicular stem cell activity and vascular health, addressing three major hair‑loss pathways simultaneously.
Indications and Mechanistic Rationale: Joint & Cartilage Repair
Explains exosome‑driven collagen and bone protein synthesis, enhanced by >20 growth factors and hyperPRP to improve nutrient delivery in poorly vascularized joints.